| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.35 | 2e-08 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.29 | 4e-08 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.21 | 6e-08 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.19 | 1e-07 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.24 | 2e-07 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.27 | 3e-07 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.26 | 4e-07 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-07 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.17 | 7e-07 |